L&T Technology Services and Critical Manufacturing to Support Danfoss’ Smart Manufacturing Journey
24.5.2023 11:30:00 EEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced its partnership with Critical Manufacturing, the provider of innovative, future-ready Manufacturing Execution Systems (MES). The strategic alliance initially sees the companies working with the multi-national engineering group, Danfoss, to implement a comprehensive digital framework that harnesses cutting-edge technologies and next-gen capabilities.
LTTS works with plant operators worldwide to optimize efficiency, improve productivity, and simplify operations while ensuring compliance with global sustainability standards. The Critical Manufacturing MES is designed from the ground-up to embrace Industry 4.0 technologies and provide a comprehensive pathway to smart manufacturing of sophisticated and complex products.
Abhishek Sinha, Chief Operating Officer and Board Member at L&T Technology Services, said, “The advanced Critical Manufacturing MES complements our industry-leading technology services. Our combined expertise and understanding of the markets we serve, supported by the most modern MES platform for Industry 4.0 success, will enable us to drive better business outcomes for our manufacturing and industrial clients.”
The selection of the Critical Manufacturing MES is part of a Smart Manufacturing Journey for Danfoss, with aims to achieve greater visibility, create transparency, enhance quality, secure IT/OT operations, and faster time to market. The platform will help standardize operations and processes to improve business process outcomes, compliance, and risk management.
“We selected the Critical Manufacturing MES because of its best of suite capabilities that allows users to take advantage of different functionalities within the same unified architecture which is expected from a modern MOM platform,” comments Tarun Chopra, Sr. Director, Head of Manufacturing Service, Danfoss Group IT. “The product has been designed for the future and will enable us to drive innovation within our business. The improvement in operational efficiency and cost management control gives us a clear return on investment and will enable us to respond more quickly to changing market demands.”
Danfoss has a large global presence with 97 factories in more than 20 countries worldwide. The initial MES deployment will be within the Danfoss Climate Solutions segment. This segment is focused on leading the way to a greener future with integrated, energy-efficient heating and cooling solutions that enhance sustainability across areas including buildings, cold chains, industry, and infrastructure.
LTTS offers consulting, engineering, and implementation services to drive global digital transformation initiatives across sectors including semiconductors, electronics, medical devices, and discrete manufacturing. These are sectors where the Critical Manufacturing MES offers rich functionality and is recognized as being one of the most innovative, flexible, and comprehensive platforms to support businesses on their journey to Industry 4.0.
Chopra continues, “While the Critical Manufacturing MES is being implemented in our Climate Solutions segment, we are also in the process of defining a global MES roadmap. The ease of deployment of the platform and its performance is an important element as we continue our pathway to digitalization and standardization throughout the global Danfoss group.”
“The use of DevOps within our platform means that new functionality and upgrades can be quickly and easily deployed and new sites added, ensuring the system is always future-ready,” comments Augusto Vilarinho, Head of Global Sales at Critical Manufacturing . “This supports Danfoss, LTTS and Critical Manufacturing’s aligned visions to take manufacturing to a future state that will deliver new benchmarks in the levels of efficiency, quality, agility, and sustainability.”
“The Danfoss digitalization project is an important starting point for our partnership. Going forward, we will work together to uncover opportunities and drive better business outcomes for our joint global customers. Together, we will engineer a sustainable tomorrow and build a better future for the world,” adds LTTS’ COO Abhishek Sinha.
Critical Manufacturing works closely with a strong network of certified global partners to ensure customers have access to domain and application experts and are supported throughout their projects.
Vilarinho concludes, “This is an exciting time for our companies, and we are looking forward to a long relationship with Danfoss and LTTS as a strategic partner. I strongly believe that together we will reach new goals and raise the bar for manufacturing worldwide.”
About Danfoss A/S:
Danfoss engineers solutions that increase machine productivity, reduce emissions, lower energy consumption, and enable electrification. Our solutions are used in such areas as refrigeration, air conditioning, heating, power conversion, motor control, industrial machinery, automotive, marine, and off- and on-highway equipment. We also provide solutions for renewable energy, such as solar and wind power, as well as district-energy infrastructure for cities. Our innovative engineering dates back to 1933. Danfoss is family-owned, employing more than 42,000 people, serving customers in more than 100 countries through a global footprint of 97 factories. www.danfoss.com
About Critical Manufacturing
Critical Manufacturing, leader in the Gartner Magic Quadrant and a subsidiary of ASMPT, provides the most modern, flexible and configurable manufacturing execution system (MES) available. Critical Manufacturing MES helps manufacturers stay ahead of stringent product traceability and compliance requirements; reduce risk with inherent closed-loop quality; integrate seamlessly with enterprise systems and factory automation, and provide deep intelligence and visibility of global production operations.
As a result, our customers are Industry 4.0 ready. They can compete effectively and profitably by easily adapting their operations to changes in demand, opportunity, or requirements, anywhere, at any time. For more information, visit www.criticalmanufacturing.com
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 22,200 employees spread across 22 global design centers, 28 global sales offices and 99 innovation labs as of March 31, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005684/en/
Contact information
Media Contact:
Aniruddha Basu
L&T Technology Services Limited
E: aniruddha.basu@ltts.com
T: +91-80-67675707
Anindita Sarkar
L&T Technology Services Limited
E: anindita.sarkar@ltts.com
T: +91-80-67675000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom